Are Emerging MET Inhibitors Meeting Expectations in Lung Cancer?
Cancer Network spoke with Karen L. Reckamp, MD, of City of Hope at ASCO 2019 about data on emerging MET inhibitors in the treatment of lung cancer patients.
Cancer Network spoke with Karen L. Reckamp, MD, medical oncologist at City of Hope, about trial data presented at ASCO 2019 on emerging MET inhibitors for the treatment of lung cancer, as well as whether these options are meeting expectations. Dr. Reckamp was a discussant at an educational session at ASCO entitled, "New Drugs and Resistance: Have We MET Expectations?"
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
